Nano-carrier | Method of synthesis | Components | Size (nm) | Zeta potential (mV) | Route of administration of nanocarrier | EE (%) | DL (%) | Dose (I.U./kg) (min/max) | PA (%) | Ref |
---|---|---|---|---|---|---|---|---|---|---|
Chitosan-insulin | Graft polymerization | Carboxylated chitosan + methyl methacrylate | 251 to 319 | –22 to –26.4 | Oral | 85 | 11.9 | 15 (min) 100 (max) | 9.7 | [77] |
Polyelectrolyte complexes + oily dispersion system | Chitosan + Oleic acid + Plurol oleique + Labrasol | 108 | 29.97 | Oral | 30.38 to 78.81 | – | 50 | 7 | [76] | |
Iionotropic pre-gelation + polyelectrolyte complexation | Chitosan + Alginate | 748 | −5.6 | Oral | 72.8 | 9.9 | 25 (min) 100 (max) | 7.1 to 3.4 | [79] | |
Polyelectrolyte complexation | Chitosan + Dextran sulfate | 527 | −20.6 | Oral | 69.3 | 2.3 | 50 (min) 100 (max) | 5.6 to 3.4 | [78] | |
Ionotropic gelation | Chitosan + TPP + Poloxamer 188 | 250 to 400 | 27.31 to 40.71 | Oral | 59.6 to 88.6 | 7.0 to 26.3 | 7 (min) 21 (max) | 14 to 15.3 | [60] | |
Ionotropic gelation | Chitosan + TPP | 269 to 688 | 21.8 to 49.8 | Oral | 38.5 to 78.5 | 60.8 | 50 (min) 100 (max) | – | [64] | |
Ionotropic gelation | Chitosan + TPP | 300 to 400 | 54 to 25 | Pulmonary | 87.4 to 96.7 | 19 to 55 | 5 | – | [68] | |
Polyelectrolyte complexation | Chitosan | 200 to 500 | 8.8 to 22 | – | 81.4 to 94.8 | 90 | – | – | [67] | |
Ionotropic gelation | Chitosan + Poly(ç-glutamic acid) | 110 to 150 | −23.7 to 33.4 | Oral | 56.8 | 14.9 | 15 (min) 30 (max) | – | [70] | |
Ionotropic complexation + coacervation | Chitosan + Dextran sulfate + Alginate | 423 to 850 | – | Oral | 3 to 94 | 5 to 13 | – | – | [71] | |
Coacervation method | Chitosan + Eudragit L100-55 | 135 to 199 | −20.7 to −27.9 mV | Oral | 3.38 | 30.56 | – | – | [72] | |
W/O/W multiple emulsion + polyelectrolyte cross-linking | Chitosan + Alginate + Calcium chloride + Labrafac CC + Phospholipid + Span 80 + Cremorphor EL | 488 | −62.25 | Oral | 47.3 | – | 25 (min) 50 (max) | 8.19 to 7.84 | [74] | |
Polyelectrolyte complexation | Chitosan + γ-PGA | 185.1 to 198.4 | 29.9 to 27.8 | Oral | 40.1 to 55.1 | 5.2 to 14.1 | 30 | 13.0 | [65] | |
PLGA-Insulin | Reverse micelle–solvent evaporation method | PLGA + Phospholipid + PVA | 102 to 428 | −12 to −22 | Oral | 51.5 to 90.4 | 4 | 20 | 7.7 | [82] |
Emulsion solvent diffusion method | PLGA + Hp55 | 169 | – | Oral | 65.41 | 3.17 | 20 | 6.27 | [47] | |
W/O/W solvent evaporation technique | PLGA + Chitosan + Pluronic 188 | 134.4 | 43.1 | Oral | 52.76 | 1.29 | 15 | 10.5 | [87] | |
W/O/W solvent evaporation technique | PLGA + Pluronic 188 | 121.3 | −1.72 | Oral | 46.87 | 1.14 | 15 | 7.6 | [87] | |
Hydrophobic ion pairing + emulsion solvent diffusion method | PLGA + Sodium oleate + PVA | 161 | −33.4 | Oral | 91.2 | – | 20 | 11.5 | [88] | |
W/O/W double emulsion method | Poly(d,l-lactide-co-glycolide) + poly(ethylene glycol) | 120 to 355 | – | – | 95 | – | – | – | [89] | |
W/O/W double emulsion method | β-cyclodextrin-PLGA | 120 to 355 | – | – | 95 | – | – | – | [89] | |
Double-emulsion solvent evaporation method | PLGA + PEG + Folate | ∼260 | – | Oral | 87 | ∼6.5 | 50 | – | [90] | |
Dextran-insulin | Emulsion method | Dextrans + Epichlorohydrin + vitamin B(12) | 160 to 250 | – | Oral | 45 to 70 | 2 to 4 | 20 | 11.4 to 26.5 | [102] |
Ionotrophic gelation + polyelectrolyte complexation | Dextran + Alginate + Poloxamer + Chitosan + BSA | 396 | −38.2 | Oral | – | – | 50 | 13 | [103] | |
Nanoemulsion dispersion + triggered instantaneous particle gelation | Dextran + Alginate + Chitosan + PEG + BSA | >1842 (90 %) >812 (50 %) | −7 | Oral | 85 | – | 25 (min) 100 (max) | 42 to 10 | [104] | |
Polyalkylcyanoacrylate-insulin | Microemulsion | Isopropyl myristate + Labrasol + Plurol Oleique + Ethyl (2) cyanoacrylate | 200 to 400 | −22 to −11.4 | Oral | 16 to 32.6 | 1.82 to 0.62 | 100 | – | [109] |
Microemulsion | Isopropyl myristate + Labrasol + Plurol Oleique + butyl (2) cyanoacrylate | 200 to 400 | −21.5 to −6.5 | Oral | 11.5 to 52.3 | 1.31 to 0.99 | 100 | – | [109] | |
– | Polybutylcyanoacrylate + Tween 20 | 78 | – | Oral | – | – | 50 | 15.5 | [110] | |
– | Polybutylcyanoacrylate + Tween 20 + Soyabean oil + vitamin E | 67 | – | Oral | – | – | 50 | 22.4 | [110] | |
Solid lipid-insulin | W/O/W double emulsion technique | Cetyl palmitate | 361 | −3.4 | Oral | 43 | – | 50 | 5 | [115] |
– | Lecithin + stearic acid + ploxamer + wheat germ agglutinin-N-glutamyl-phosphatidyl-ethanolamine | 75.3 | −13.11 | Oral | 17.89 to 23.72 | – | 50 | 6.08 | [117] | |
Reverse micelle-double emulsion | Sodium cholate (SC) + soybean phosphatidylcholine + stearic acid + palmitic acid | 114.7 | −51.36 | – | 97.78 | 18.92 | – | – | [118] | |
W/O/W emulsion technique | – | 2 µ | – | Pulmonary | 56.32 to 66.02 | – | 8 | 35.62 | [124] | |
Double emulsion method | Stearic acid/octadecyl alcohol/cetyl palmitate/glyceryl monostearate/glyceryl palmitostearate/glyceryl tripalmitate/glyceryl behenate | 213 to 444.8 | −9 | Oral | – | – | 50 | 2.92 to 4.53 | [123] | |
Solvent emulsification-evaporation | Witepsol 85E | 243 | −25 | Oral | 43.6 | 2.1 | 25 | 8.26 | [122] | |
Solvent emulsification-evaporation | Witepsol 85E + chitosan | 470 | 34 | Oral | 52.2 | 1.4 | 25 | 17.7 | [122] | |
Targeted insulin nanoparticle | Ionotropic gelation method | N-trimethyl chitosan chloride + CSKSSDYQC peptide + | 342 | 3 | Oral | 55.4 | – | 50 | 5.66 | [26] |
Nanoprecipitation | PLA-PEG + human polyclonal IgG Fc | 63 | −5.6 | Oral | – | 0.5 | 1.1 | 13.7 | [128] |